InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,346.56
(
0.00%
)
US TECH 100
17,101.60
(
-4.73%
)
Dow Jones
39,737.26
(
0.00%
)
Brent Oil
75.82
(
-1.70%
)
Bitcoin
50,103.36
(
-13.41%
)
Post# of 252785
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 60
Posts 11544
Boards Moderated 0
Alias Born 07/16/2006

jbog

Member Level

Re: walldiver post# 49735

Monday, 07/16/2007 5:51:24 PM

Monday, July 16, 2007 5:51:24 PM

Post# of 252785
wall,

I wrote to brian and he replied to me already.


On 7/16/07, Jbogd1 wrote:
nice story "but" the facts need a little cleaning. Both Iressa and Tarceva "failed" their 1st line studies.

Neither Iressa nor Tarceva are approved 1st line, so for Imclone to get close could be interesting. Tarceva and Iressa actually proved detrimental to 1st line patients.


thanks

==============================================================

Reply:
Hi,

I never claimed either are approved as first line treatments for NSCLC.

Brian
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up